Esperion Therapeutics, Inc. filed an 8-K/A to provide the required financial statements and pro forma financial information regarding its acquisition of Corstasis Therapeutics Inc. The filing includes audited consolidated financial statements for Corstasis for the years 2024 and 2025, along with unaudited pro forma condensed combined balance sheet and statements of earnings for the fiscal year 2025. Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular-related therapies.
